Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2879 - Metabolic Syndrome and Inflammation in Castration Resistant Prostate Cancer (CRPC) patients (pts) treated with Abiraterone (abi) and Enzalutamide (enza)

Date

11 Sep 2017

Session

Poster display session

Presenters

Vincenza Conteduca

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

V. Conteduca1, O. Caffo2, L. Galli3, A. Maugeri4, E. Scarpi5, F. Maines2, V. Chiuri6, C. Lolli1, S. Kinspergher2, G. Schepisi1, M. Santoni7, D. Santini8, L. Fratino9, S.L. Burgio1, S. Salvi10, C. Menna1, U. De Giorgi1

Author affiliations

  • 1 Department Of Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 2 Department Of Oncology, Ospedale Santa Chiara, 38122 - Trento/IT
  • 3 Oncology, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa/IT
  • 4 Oncology Pharmacy, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 5 Biostatistics And Clinical Trials, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 6 Department Of Oncology, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 7 Department Of Oncology, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT
  • 8 Department Of Oncology, Campus Bio-Medico di Roma, 128 - Roma/IT
  • 9 Medical Oncology Department, Centro di Riferimento Oncologico di Aviano, 33081 - Aviano/IT
  • 10 Biosciences Laboratory, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
More

Resources

Abstract 2879

Background

Metabolic syndrome (MS) and inflammation (INF) alterations are hallmarks of cancer progression. The study aimed to firstly assess the relationship between MS and INF and its impact on progression-free/overall survival (PFS/OS) in CRPC pts.

Methods

We retrospectively evaluated CRPC pts treated with abi and enza in 7 Italian Institutes between March 2011 and October 2016. MS was defined by modified Adult Treatment Panel III criteria, and INF characterized by the presence of at least 1 of these criteria: NLR≥3, elevated VES or C-reactive protein (CRP) levels.

Results

Eighty-three of 551 pts evaluated (15%) met MS criteria at baseline, whereas for 40 (8.5%) this occurred during treatment. No significant difference of MS incidence and cardiometabolic toxicities were reported between abi or enza. Pts with MS (MS+) showed a greater INF profile compared to MS- (79% vs 28%, p 

Conclusions

The presence of MS is strongly associated with INF. Pre-treatment identification of MS and INF alterations may represent an available and easy to perform tool for a better prognostication of CRPC pts treated with abi or enza. A prospective evaluation is warranted.

Clinical trial identification

None

Legal entity responsible for the study

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS

Funding

None

Disclosure

V. Conteduca, U. De Giorgi: Speaker honoraria or travel support from Astellas, Janssen-Cilag and Sanofi- Aventis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.